linjc16/ctgov huggingface dataset:
Role of TAP and RS Block in Reduction of Postoperative Pain for Gynecological Surgical Laparoscopic Procedures

Study Overview
=================
Brief Summary
-----------------
The present study aims to demonstrate the effectiveness of loco-regional wall anesthesia of the transversus abdominis plane block (TAP block) and the rectus sheath block (RS block), compared to intravenous analgesia, in terms of pain reduction, postoperative analgesic drugs consumption, patient satisfaction and decrease of LOS (length of stay), in patients undergoing benign gynecological laparoscopic surgical procedures.

Official Title
-----------------
The Role of Transversus Abdominis Plane Block and Rectus Sheath Block in Reduction of Postoperative Pain for Gynecological Benign Surgical Laparoscopic Procedures: a Randomized Controlled Trial

Conditions
-----------------
TAP and RS Block

Intervention / Treatment
-----------------
* Procedure: TAP block and RS block + General Intravenous Anesthestic
* Drug: General Intravenous Anesthetic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing benign laparoscopic gynecological surgery age between 18 and 75 years BMI >18 e <35 ECOG Performance Status 0-1 Exclusion Criteria: age < 18 or > 75 years BMI <18 or > 35 ECOG Performance Status >1 Allergy to local anesthetics Allergy to NSAIDs Chronic kidney failure > II class Systemic neoplastic disease actual or previous Actual pregnancy Active or recent pelvic inflammation Persistent coagulopathy Previous opioids consumption for chronic pain Neurological or cognitive disorders Conversion from laparoscopic to open surgery Onset of intraoperative complications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ALR<br> | Procedure: TAP block and RS block + General Intravenous Anesthestic<br>* transversus abdominis plane block and rectus sheath block<br>|
| Active Comparator: EV<br> | Drug: General Intravenous Anesthetic<br>* General Intravenous Anesthetic<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative pain in the first 72 hours after gynecological surgical procedures | postoperative pain in the first 72 hours after gynecological surgical procedures | postoperative pain in the first 72 hours after gynecological surgical procedures | 
| analgesic consumption in the first 72 hours after gynecological surgical procedures | analgesic consumption in the first 72 hours after gynecological surgical procedures | analgesic consumption in the first 72 hours after gynecological surgical procedures |
Effectiveness of Port Site Bupivacaine Injection in Postoperative Pain Reduction After Lap. Chole

Study Overview
=================
Brief Summary
-----------------
To determine the effectiveness of port site bupivacaine infiltration in postoperative pain reduction after laparoscopic cholecystectomy.

Detailed Description
-----------------
The study is being done to determine the effectiveness of port site bupivacaine infiltration in postoperative pain reduction after laparoscopic cholecystectomy.

Official Title
-----------------
A Randomized Controlled Trial of Port Site Subcutaneous Injection of Bupivacaine to Determine the Effectiveness of Postoperative Pain Relief After Laparoscopic Cholecystectomy

Conditions
-----------------
Pain, Postoperative

Intervention / Treatment
-----------------
* Drug: 0.25% Bupivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of both the gender of age >18 years and <45years Patients undergoing elective laparoscopic cholecystectomy under general anesthesia. Patients with A.S.A grade I and II. Exclusion Criteria: Patients with known allergic reactions to local anesthetics. Patients converted to open procedure. Patients developing intra-operative complications. Patients undergoing for laparoscopic cholecystectomy for acute cholecystitis. Patients with obesity and chronic illness. Patients with history of opioids, steroids, NSAIDs and alcohol use.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Group A: Study group: Patient receiving intervention i.e 20ml of 0.25% buvivacaine infiltration at laparoscopic port site. Group B: Control group: no intervention
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bupivacaine group<br>Patient receiving 20ml of inj. 0.25% Bupivacaine at laparoscopic port site | Drug: 0.25% Bupivacaine<br>* 20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.<br>* Other names: Bupivacain;|
| No Intervention: Placebo group<br>No drug infiltration at laparoscopic port site | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post laparoscopic port site pain assessment | Pain assessment by Visual Analog Scoring system scoring from 0 to 10, where 0 means no pain and 10 means worst possible, unbearable excruciating pain. | Pain assessment from 0hour (patient received in recovery room) till 12hours postoperatively at interval of 3hours i.e. 0,3,6,9,12 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
#Post operative pain, #laparoscopic cholecystectomy
Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical trial is to demonstrate that wavefront-guided LASIK is safe and effective for the correction of myopic refractive errors.

Official Title
-----------------
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided LASIK Correction of Myopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4IR™ Excimer Laser

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Device: LASIK correction of myopic refractive errors


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or greater Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better Uncorrected visual acuity (UCVA) of 20/40 or worse Less than 0.75D difference between cycloplegic and manifest refraction sphere. Demonstration of refractive stability Anticipated post-operative stromal bed thickness of at least 250 microns Willing and capable of returning for follow-up examinations for the duration of the study. Exclusion Criteria: Women who are pregnant, breast-feeding, or intend to become pregnant over the course of the study Concurrent use of topical or systemic medications that may impair healing History of any medical conditions that could affect wound healing History of prior intraocular or corneal surgery, active ophthalmic disease, or other ocular abnormality Evidence of keratoconus, corneal irregularity, or abnormal topography in the operative eye(s) Known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: wavefront-guided LASIK<br>LASIK correction of myopic refractive errors. Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System. | Device: LASIK correction of myopic refractive errors<br>* Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Eyes With Loss of More Than 2 Lines Best Spectacle Corrected Visual Acuity (BSCVA) |  | 6 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better |  | 6 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
refractive, LASIK
A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy and safety Genexol-PM(CrEL-free polymeric micelle formulated paclitaxel)and gemcitabine in untreated metastatic NSCLC patients

Official Title
-----------------
A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: Genexol-PM/Gemcitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age over 18 histologically or cytologically confirmted non-small cell lung cancer stage IIIb with pleural effusion or stage IV ECOG PS 0-2 at least one measurable lesion expected life span more than 3 months normal bone marrow, liver, renal function no prior chemotherapy or radiotherapy except for whole brain radiotherapy for symptomatic brain metastases more than 6 months from the last adjuvant chemotherapy Exclusion Criteria: active infection severe comorbitidies pregnant or lactating women other invasive malignancies poorly controlled symptomatic brain metastases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Genexol-PM/Gemcitabine<br> | Drug: Genexol-PM/Gemcitabine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall response rate |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression free survival |  | one year | 
| overall survival |  | one year | 
| toxicities |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non-small cell lung cancer, genexol-PM, paclitaxel, gemcitabine
The Role of Extracellular pH on Spermatozoa's Directional Movement in Vitro

Study Overview
=================
Brief Summary
-----------------
The purpose of this research project is to determine whether or not the directional movement of spermatozoa is influenced by a pH gradient by examining spermatozoa in vitro.

Official Title
-----------------
The Role of Extracellular pH on Spermatozoa's Directional Movement in Vitro

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Other: Extracellular pH


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal semen sample

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Extracellular pH|Extracellular pH gradient|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Directional Movement | Observing whether cells move towards alkaline or acidic | 5 minutes |
Myocellular Signalling in Skeletal Muscle

Study Overview
=================
Brief Summary
-----------------
The study will investigate myocellular signalling in skeletal muscle after insulin-stimulation and exercise in healthy young men

Official Title
-----------------
Insulin-dependent and Exercise-induced Myocellular Signalling in Skeletal Muscle

Conditions
-----------------
Exercise, Insulin Sensitivity

Intervention / Treatment
-----------------
* Drug: Insulin
* Other: Exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy informed consent habitual training (2-5 h/week) VO2max of 40-60 ml/min/kg lean mass 55-65 kg Exclusion Criteria: smoker allergy towards insulin chronic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Insulin-stimulation<br>2 h insulin-clamp | Drug: Insulin<br>* 2 h insulin clamp<br>|
| Experimental: Exercise<br>10 min of maximal exercise | Other: Exercise<br>* Cycling exercise<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in muscle phospho-proteome signature | proteomic analysis of mixed muscle homogenate | Before and after 10 minutes of exercise, as well as before and after a 2 hour insulin stimulation |
Prevalence of Dyschromatopsia in Glaucoma Patients

Study Overview
=================
Brief Summary
-----------------
Glaucoma is a progressive disease resulting in loss of retinal nerve cells and their axons (retinal nerve fibers). Retinal nerve fibers are ordered in a special manner when they enter the optic nerve. Hence, damage to the retinal nerve fibers by glaucoma results in visual field defects at certain locations. Furthermore, the retinal nerve fiber layers from different receptors for different colors are ordered in a special manner as well. Thus, it is possible that glaucomatous damage causes color vision dysfunction (dyschromatopsia). At the moment there is disagreement whether dyschromatopsia occurs at early- to mid-stage or only in end-stage glaucoma. By testing color vision in glaucoma patients the prevalence of dyschromatopsia in glaucoma and in different stages of the disease will be investigated.

Official Title
-----------------
Prevalence of Dyschromatopsia in Glaucoma Patients

Conditions
-----------------
Open Angle Glaucoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of open angle glaucoma visual acuity >/= 20/50 age >/= 18 (no upper limit) male or female gender Exclusion Criteria: other type of glaucoma age <18 other retinal disease (e.g. age related macular degeneration) other disease affecting the optic nerve or the retinal nerve fibers known color blindness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Result from Ishihara Test | Color vision will be tested once by Ishihara plates. Both eyes will be tested separately. | Visit 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glaucoma stage | Visual field will be tested with 30-2 Humphrey visual field full threshold test. Visual field defects will we graded following the Hodapp-Anderson-Parrish Scale (Hodapp E, Parrish RK, Anderson DR. Classification of Defects in Clinical Decisions in Glaucoma. St. Louis: Mosby, 1993:52-61). | Visit 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
OAG
Retrospective Observational Study of Cotrimoxazole Dosing in Intensive Care Unit

Study Overview
=================
Brief Summary
-----------------
Trimethoprim/sulfamethoxazole (TMP/SMX, cotrimoxazole) is the first-line therapy for Pneumocystis jirovecii pneumonia and bacterial infections in critically ill patients, where acute kidney injury (AKI) and renal replacement therapy (RRT) are regularly observed. Both may change half-life and subsequent concentrations. Specifically, Trimethoprim (TMP) is eliminated renally, whereas sulfamethoxazole (SMX) elimination is 80%metabolic/20%renal. Despite decades of cotrimoxazole use, data in acute kidney injury (AKI) are scarce and no consensus on dosing strategy has been established. Besides, pharmacodynamic parameter has not been determined, leading to an uncertainty on the dosing regimen.

Detailed Description
-----------------
The objective is to compare the plasma concentrations of patients with acute renal failure (ARF) or requiring extra renal replacement therapy (RRT) with those of patients without these characteristics to look for differences in concentration.

Official Title
-----------------
Single-center Retrospective Observational Study of Cotrimoxazole Dosing in Intensive Care Unit

Conditions
-----------------
Acute Kidney Injury

Intervention / Treatment
-----------------
* Other: Collect data of medical record


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient hospitalized in Intensive Care Units between October 2020 and July 2021 with infection treated with cotrimoxazole Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients in Intensive Care unit<br>patients in Intensive Care unit with infection treated with cotrimoxazole will be included. Data will be collected of medical record. | Other: Collect data of medical record<br>* Collect data of medical record: plasma concentrations of cotrimoxazole, demographic data (age, weight, height), data on the use of an extra renal replacement therapy (RRT) (date, type, number of sessions and duration of extra renal replacement therapy (RRT))<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| plasma concentrations of cotrimoxazole (mg/l) | pharmacokinetic cotrimoxazole | From the antibiotic initiation until the patient is discharged from the ICU with a maximal time frame of 10 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cotrimoxazole, Acute Kidney Injury, renal replacement therapy, pharmacodynamic
Objective Assessment of Physical Activity in Older Adults

Study Overview
=================
Brief Summary
-----------------
The purpose of the present study is to evaluate the validity of 2 objective measures of physical activity among older adults. In addition, the investigators will examine the influence of functionality, walking aids, walking speed and step length on the accuracy.

Conditions
-----------------
Functionality, Strength, Validity During Daily Activities, Physical Activity, Older Adults

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 70 years Exclusion Criteria: recent cardiovascular event vestibular disorder or fracture (4 months) severe dementia oxygen supplementation during daily activities not able to perform daily activities

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| elderly (> 70 y)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |